Endothelial, Vascular and Sympathetic Alterations As Therapeutic Targets in Chronic Heart Failure

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Mar 29

PMID 36979781

Authors

Fosca Quarti-Trevano

Raffaella DellOro

Cesare Cuspidi

Pasquale Ambrosino

Guido Grassi

Affiliations

Soon will be listed here.

Abstract

Vascular and sympathetic abnormalities characterize chronic heart failure (CHF). Alterations include (1) a reduction in arterial distensibility, (2) endothelial dysfunction, (3) a decrease in arterial compliance and a parallel increase in arterial stiffness, and (4) sympathetic cardiovascular activation. Altogether, these alterations represent important targets in therapeutic interventions, because they display an independent negative impact on the disease prognosis, favouring disease progression and the development of cardiovascular complications with direct and indirect mechanisms. The present review will examine the effects of the different therapeutic interventions targeting the vascular/sympathetic alterations detected in CHF. Non-pharmacological, pharmacological and device-based treatments will be discussed in detail, highlighting the possible mechanisms responsible for the vascular/sympathetic effects of each intervention. Finally, the unmet goals in treatment in relation to endothelial and adrenergic targets will be also discussed.

Citing Articles

Comparative effects of sacubitril/valsartan and ACEI/ARB on endothelial function and arterial stiffness in patients with heart failure: a protocol for systematic review and meta-analysis.

Ma Z, Fu Z, Li N, Huang S, Chi L BMJ Open. 2024; 14(9):e088744.

PMID: 39260836 PMC: 11409383. DOI: 10.1136/bmjopen-2024-088744.

Physiological Correlates of Hypnotizability: Hypnotic Behaviour and Prognostic Role in Medicine.

Malloggi E, Santarcangelo E Brain Sci. 2023; 13(12).

PMID: 38137080 PMC: 10742099. DOI: 10.3390/brainsci13121632.

References

Bunsawat K, Ratchford S, Alpenglow J, Park S, Jarrett C, Stehlik J . Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. J Appl Physiol (1985). 2020; 130(1):256-268. PMC: 7944927. DOI: 10.1152/japplphysiol.00454.2020. View

Muhlen B, Millgard J, Lind L . Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects. Clin Exp Pharmacol Physiol. 2001; 28(5-6):381-5. DOI: 10.1046/j.1440-1681.2001.03465.x. View

do Vale G, Ceron C, Gonzaga N, Simplicio J, Padovan J . Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Curr Hypertens Rev. 2018; 15(1):22-31. DOI: 10.2174/1573402114666180918102735. View

Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H . Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med. 2007; 48(12):1993-2000. DOI: 10.2967/jnumed.107.045427. View

Azzam O, Matthews V, Schlaich M . Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. Curr Opin Nephrol Hypertens. 2022; 31(2):135-141. DOI: 10.1097/MNH.0000000000000767. View

Cohn J, Pfeffer M, Rouleau J, Sharpe N, Swedberg K, Straub M . Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003; 5(5):659-67. DOI: 10.1016/s1388-9842(03)00163-6. View

MacDonald J, Kennedy N, Struthers A . Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart. 2004; 90(7):765-70. PMC: 1768327. DOI: 10.1136/hrt.2003.017368. View

Kaneko Y, Floras J, Usui K, Plante J, Tkacova R, Kubo T . Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003; 348(13):1233-41. DOI: 10.1056/NEJMoa022479. View

Biegus J, Voors A, Collins S, Kosiborod M, Teerlink J, Angermann C . Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2022; 44(1):41-50. PMC: 9805406. DOI: 10.1093/eurheartj/ehac530. View

10.

Giannattasio C, Achilli F, Grappiolo A, Failla M, Meles E, Gentile G . Radial artery flow-mediated dilatation in heart failure patients: effects of pharmacological and nonpharmacological treatment. Hypertension. 2001; 38(6):1451-5. DOI: 10.1161/hy1201.096528. View

11.

Hasdai D, Lerman A . The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz. 1999; 24(7):544-7. DOI: 10.1007/BF03044226. View

12.

Bhm M, Anker S, Mahfoud F, Lauder L, Filippatos G, Ferreira J . Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. 2022; 44(5):396-407. PMC: 9890225. DOI: 10.1093/eurheartj/ehac693. View

13.

Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2):257-65. DOI: 10.1016/s0735-1097(01)01746-6. View

14.

Fortini F, Vieceli Dalla Sega F, Marracino L, Severi P, Rapezzi C, Rizzo P . Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape. Biomedicines. 2021; 9(8). PMC: 8393382. DOI: 10.3390/biomedicines9080997. View

15.

Greene S, Fonarow G, Butler J . Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circ Heart Fail. 2020; 13(6):e007132. DOI: 10.1161/CIRCHEARTFAILURE.120.007132. View

16.

Bocchi E, Salemi V . Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019; 18(5):393-402. DOI: 10.1080/14740338.2019.1612873. View

17.

Gong X, Hu M, Li M . Relationship of arterial tonometry and exercise in patients with chronic heart failure: a systematic review with meta-analysis and trial sequential analysis. BMC Cardiovasc Disord. 2022; 22(1):345. PMC: 9341099. DOI: 10.1186/s12872-022-02792-6. View

18.

Theofilis P, Sagris M, Oikonomou E, Antonopoulos A, Siasos G, Tsioufis C . Inflammatory Mechanisms Contributing to Endothelial Dysfunction. Biomedicines. 2021; 9(7). PMC: 8301477. DOI: 10.3390/biomedicines9070781. View

19.

Weber T, Chirinos J . Pulsatile arterial haemodynamics in heart failure. Eur Heart J. 2018; 39(43):3847-3854. PMC: 6234849. DOI: 10.1093/eurheartj/ehy346. View

20.

Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif J . Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure. Am Heart J. 2005; 149(5):938.e1-7. DOI: 10.1016/j.ahj.2004.11.011. View